California Public Employees Retirement System Macrogenics Inc Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $2.2 Million - $3.83 Million	-107,400 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$18.99 - $33.2 $196,375 - $343,321	-10,341 Reduced 8.78%	107,400 $3.42 Million
Q4 2020 Feb 02, 2021	SELL	$19.41 - $26.0 $33,909 - $45,422	-1,747 Reduced 1.46%	117,741 $2.69 Million
Q3 2020 Nov 05, 2020	BUY	$24.69 - $31.6 $555,228 - $710,620	22,488 Added 23.18%	119,488 $3.01 Million
Q2 2020 Aug 12, 2020	SELL	$5.2 - $29.12 $47,330 - $265,050	-9,102 Reduced 8.58%	97,000 $2.71 Million
Q1 2020 May 12, 2020	SELL	$4.28 - $12.11 $16,264 - $46,018	-3,800 Reduced 3.46%	106,102 $618,000
Q4 2019 Jan 27, 2020	BUY	$7.95 - $12.27 $117,660 - $181,596	14,800 Added 15.56%	109,902 $1.2 Million
Q3 2019 Oct 31, 2019	BUY	$12.44 - $17.48 $1 Million - $1.41 Million	80,400 Added 546.86%	95,102 $1.21 Million
Q2 2019 Aug 15, 2019	BUY	$14.51 - $19.71 $29,745 - $40,405	2,050 Added 16.2%	14,702 $249,000
Q1 2019 May 03, 2019	BUY	$11.11 - $25.6 $140,563 - $323,891	12,652 New	12,652 $227,000

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

Bellevue Group Ag Kuesnacht, V8

9.93M
Shares

$32.4 Million
0.55% of portfolio
Armistice Capital, LLC New York, NY

6.26M
Shares

$20.4 Million
0.34% of portfolio
Black Rock Inc. New York, NY

5.4M
Shares

$17.6 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.36M
Shares

$14.2 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.54M
Shares

$11.5 Million
0.01% of portfolio

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account